Reuters -- Switzerland’s Nycomed aims to draw on buoyant junk bond markets and new cash from its private-equity owners to fund a planned buyout of Solvay’s (SOLB.BR) drugs unit, people familiar with the matter said.
Reuters -- Switzerland’s Nycomed aims to draw on buoyant junk bond markets and new cash from its private-equity owners to fund a planned buyout of Solvay’s (SOLB.BR) drugs unit, people familiar with the matter said.
